{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:29:04Z","timestamp":1787840944830,"version":"build-2784847793"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Metaplastic breast cancer (MpBC) is a rare subtype of breast cancer characterized by poor prognosis and lack of treatment guidance. It is notably resistant to conventional chemotherapy. Currently, immunotherapy is becoming a promising option for multiple tumor types, including triple-negative breast cancer. This report presents a case of triple-negative MpBC that achieved a complete response with a combination of chemotherapy and immune checkpoint inhibitors. We examined the tumor\u2019s imaging and histological features, along with the treatment regimen and efficacy. Notably, no major toxicities related to immunotherapy were observed. To our knowledge, this is the first case report demonstrating the effectiveness of lambrolizumab in combination with the GP chemotherapy regimen for treating triple-negative breast cancer in general and specifically metastatic MpBC.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_285_25","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:07:02Z","timestamp":1756998422000},"page":"955-959","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Complete response in a patient with metastatic metaplastic breast cancer treated with immune checkpoint inhibitor and chemotherapy: A case report and a review of the literature"],"prefix":"10.4103","volume":"21","author":[{"given":"Jinghua","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China"},{"name":"Department of Oncology, People\u2019s Hospital of Zhangdian District, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Intensive Care Unit, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shandong First Medical University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, People\u2019s Hospital of Zhangdian District, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baishan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, People\u2019s Hospital of Hantai, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxin","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Oncology, People\u2019s Hospital of Zhangdian District, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, People\u2019s Hospital of Zhangdian District, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, People\u2019s Hospital of Zhangdian District, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, People\u2019s Hospital of Zhangdian District, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"R1-20250905","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11912-014-0431-z","article-title":"Metaplastic breast cancer: Clinical overview and molecular aberrations for potential targeted therapy","volume":"17","author":"Abouharb","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"R2-20250905","first-page":"e28551","article-title":"Metaplastic breast cancer: Characteristics and survival outcomes","volume":"14","author":"Thapa","year":"2022","journal-title":"Cureus"},{"key":"R3-20250905","first-page":"1078","article-title":"Metaplastic breast carcinoma. Rare form of mammary cancer","volume":"73","author":"Huvos","year":"1973","journal-title":"N Y State J Med"},{"key":"R4-20250905","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/1078-0432.CCR-17-0108","article-title":"Whole-exome sequencing of metaplastic breast carcinoma indicates monoclonality with associated ductal carcinoma component","volume":"23","author":"Avigdor","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R5-20250905","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/his.14091","article-title":"The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan","year":"2020","journal-title":"Histopathology"},{"key":"R6-20250905","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.breast.2018.12.004","article-title":"Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types","volume":"43","author":"Budzik","year":"2019","journal-title":"Breast"},{"key":"R7-20250905","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/tbj.13234","article-title":"Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease","volume":"25","author":"Takala","year":"2019","journal-title":"Breast J"},{"key":"R8-20250905","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.7150\/jca.40817","article-title":"Outcomes after treatment of metaplastic versus other breast cancer subtypes","volume":"11","author":"Moreno","year":"2020","journal-title":"J Cancer"},{"key":"R9-20250905","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/tbj.13416","article-title":"Metaplastic breast carcinoma: Current therapeutic approaches and novel targeted therapies","volume":"25","author":"Drekolias","year":"2019","journal-title":"Breast J"},{"key":"R10-20250905","doi-asserted-by":"crossref","first-page":"101888","DOI":"10.1016\/j.ctrv.2019.08.004","article-title":"Therapeutic landscape of metaplastic breast cancer","volume":"79","author":"Tray","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"R11-20250905","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00aeInsights: Breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R12-20250905","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/tbj.13416","article-title":"Metaplastic breast carcinoma: Current therapeutic approaches and novel targeted therapies","volume":"25","author":"Drekolias","year":"2019","journal-title":"Breast J"},{"key":"R13-20250905","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jamaoncol.2016.5281","article-title":"Targeting the PI3K\/AKT\/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: Evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab","volume":"3","author":"Basho","year":"2017","journal-title":"JAMA Oncol"},{"key":"R14-20250905","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.7150\/jca.40817","article-title":"Outcomes after treatment of metaplastic versus other breast cancer subtypes","volume":"11","author":"Moreno","year":"2020","journal-title":"J Cancer"},{"key":"R15-20250905","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ijrobp.2005.08.024","article-title":"Metaplastic carcinoma of the breast: A retrospective review","volume":"64","author":"Dave","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20250905","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/BD-170313","article-title":"Metaplastic carcinoma of the breast with mesenchymal differentiation (carcinosarcoma). A unique presentation of an aggressive malignancy and literature review","volume":"37","author":"Salemis","year":"2018","journal-title":"Breast Dis"},{"key":"R17-20250905","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10549-011-1686-9","article-title":"Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era","volume":"130","author":"Chen","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"R18-20250905","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-0780-8","article-title":"Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer","volume":"120","author":"Jung","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R19-20250905","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13058-020-01353-z","article-title":"A comprehensive overview of metaplastic breast cancer: Clinical features and molecular aberrations","volume":"22","author":"Reddy","year":"2020","journal-title":"Breast Cancer Res"},{"key":"R20-20250905","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","article-title":"Role of immunotherapy in triple-negative breast cancer","volume":"18","author":"Keenan","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R21-20250905","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.4103\/jcrt.jcrt_1867_20","article-title":"Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis","volume":"18","author":"Mittal","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"R22-20250905","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.4103\/jcrt.jcrt_41_24","article-title":"Prognostic value of tumor-infiltrating lymphocyte subtypes and microorganisms in triple-negative breast cancer","volume":"20","author":"Shi","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R23-20250905","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.4103\/jcrt.JCRT_997_20","article-title":"Tumor infiltrating lymphocytes profile and response in neoadjuvant chemotherapy-treated triple-negative breast carcinoma patients","volume":"18","author":"Ray","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"R24-20250905","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"R25-20250905","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"R26-20250905","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/jclinpath-2016-203874","article-title":"Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1","volume":"70","author":"Joneja","year":"2017","journal-title":"J Clin Pathol"},{"key":"R27-20250905","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/2153-3539.126147","article-title":"Mining genome sequencing data to identify the genomic features linked to breast cancer histopathology","volume":"5","author":"Ping","year":"2014","journal-title":"J Pathol Inform"},{"key":"R28-20250905","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1186\/s12885-022-10408-7","article-title":"Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of ?H2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases","volume":"22","author":"Voutilainen","year":"2022","journal-title":"BMC Cancer"},{"key":"R29-20250905","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2147\/OTT.S435958","article-title":"Immunotherapy combined with chemotherapy in relapse metaplastic breast cancer","volume":"16","author":"Chen","year":"2023","journal-title":"Onco Targets Ther"},{"key":"R30-20250905","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41523-017-0011-0","article-title":"Dramatic response of metaplastic breast cancer to chemo-immunotherapy","volume":"3","author":"Adams","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"R31-20250905","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.12659\/AJCR.918770","article-title":"Complete response of chemo-refractory metastatic metaplastic breast cancer to paclitaxel-immunotherapy combination","volume":"20","author":"Al","year":"2019","journal-title":"Am J Case Rep"},{"key":"R32-20250905","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1159\/000515510","article-title":"Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer","volume":"14","author":"Gorshein","year":"2021","journal-title":"Case Rep Oncol"},{"key":"R33-20250905","doi-asserted-by":"crossref","first-page":"635237","DOI":"10.3389\/fonc.2021.635237","article-title":"A case series of metastatic metaplastic breast carcinoma treated with anti-PD-1 therapy","volume":"11","author":"Kim","year":"2021","journal-title":"Front Oncol"},{"key":"R34-20250905","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1159\/000534146","article-title":"Complete response of triple-negative metaplastic carcinoma of the breast using pembrolizumab","volume":"16","author":"Ladwa","year":"2023","journal-title":"Case Rep Oncol"},{"key":"R35-20250905","doi-asserted-by":"crossref","first-page":"810747","DOI":"10.3389\/fendo.2022.810747","article-title":"Partial response after toripalimab plus anlotinib for advanced metaplastic breast carcinoma: A case report","volume":"13","author":"Fu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_285_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:32:33Z","timestamp":1787837553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_285_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_285_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-02-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}